Guardant Health (GH) stock rocketed Friday after a Food and Drug Administration panel recommended the agency approve Guardant's blood-based colon cancer screening test. X The FDA's Medical Devices Advisory Committee voted eight to one that Guardant's blood-based test, known as Shield, is safe. Six out of nine panelists said the test appears effective, and seven to two voted that the benefits outweigh the risks. If approved, Guardant's blood-based test would rival Exact Sciences' (EXAS) Cologuard, an already ...